# Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia

> **NCT01362036** · PHASE1 · TERMINATED · sponsor: **Tarix Pharmaceuticals** · enrollment: 2 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** TXA127

## Key facts

- **NCT ID:** NCT01362036
- **Lead sponsor:** Tarix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Enrollment feasibility issues, new study in design
- **Last updated:** 2016-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362036, "Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01362036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*